Savant Capital LLC Invests $210,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Savant Capital LLC acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 4,648 shares of the biopharmaceutical company’s stock, valued at approximately $210,000.

A number of other large investors also recently modified their holdings of PTCT. Point72 Asset Management L.P. boosted its stake in shares of PTC Therapeutics by 945.6% in the third quarter. Point72 Asset Management L.P. now owns 575,860 shares of the biopharmaceutical company’s stock worth $21,364,000 after acquiring an additional 643,960 shares during the period. Parkman Healthcare Partners LLC purchased a new stake in PTC Therapeutics during the 3rd quarter valued at approximately $7,234,000. State Street Corp grew its holdings in PTC Therapeutics by 5.4% during the 3rd quarter. State Street Corp now owns 2,899,040 shares of the biopharmaceutical company’s stock valued at $107,554,000 after buying an additional 149,700 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in PTC Therapeutics by 32.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 492,464 shares of the biopharmaceutical company’s stock valued at $18,270,000 after buying an additional 119,637 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in PTC Therapeutics by 7.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 706,730 shares of the biopharmaceutical company’s stock valued at $26,220,000 after buying an additional 47,902 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald increased their price objective on shares of PTC Therapeutics from $76.00 to $113.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Morgan Stanley raised shares of PTC Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $45.00 to $67.00 in a report on Friday, December 13th. Barclays increased their price objective on shares of PTC Therapeutics from $45.00 to $56.00 and gave the company an “equal weight” rating in a report on Tuesday, December 3rd. Citigroup increased their price objective on shares of PTC Therapeutics from $32.00 to $45.00 and gave the company a “sell” rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group increased their target price on PTC Therapeutics from $32.00 to $42.00 and gave the company a “sell” rating in a research report on Wednesday, December 4th. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, PTC Therapeutics has an average rating of “Hold” and a consensus target price of $58.85.

Insider Activity

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 1,265 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total transaction of $57,355.10. Following the completion of the sale, the insider now directly owns 104,783 shares of the company’s stock, valued at approximately $4,750,861.22. This trade represents a 1.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Mark Elliott Boulding sold 85,600 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $52.26, for a total value of $4,473,456.00. Following the completion of the sale, the vice president now directly owns 92,389 shares of the company’s stock, valued at $4,828,249.14. This represents a 48.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 211,737 shares of company stock worth $10,920,687. 5.50% of the stock is currently owned by insiders.

PTC Therapeutics Price Performance

PTCT stock opened at $50.42 on Thursday. The firm has a market capitalization of $3.89 billion, a P/E ratio of -8.49 and a beta of 0.62. The business’s 50-day moving average is $46.52 and its two-hundred day moving average is $41.29. PTC Therapeutics, Inc. has a 1 year low of $24.00 and a 1 year high of $54.16.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.